Amplify Weight Loss Drug & Treatment ETF Plans Annual Dividend of $0.41 (NYSEARCA:THNR)

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) announced an annual dividend on Monday, December 29th. Investors of record on Tuesday, December 30th will be paid a dividend of 0.4132 per share on Wednesday, December 31st. This represents a yield of 159.0%. The ex-dividend date of this dividend is Tuesday, December 30th.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Amplify Weight Loss Drug & Treatment ETF stock opened at $25.94 on Tuesday. The firm has a market cap of $2.85 million, a price-to-earnings ratio of 24.31 and a beta of 0.61. Amplify Weight Loss Drug & Treatment ETF has a 1 year low of $18.56 and a 1 year high of $26.30. The firm’s 50 day moving average price is $24.76 and its two-hundred day moving average price is $23.72.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent filing with the Securities & Exchange Commission.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.